B-VEC FDA Label Expansion for DEB: What It Means for Patients and CliniciansÂ
In May 2023, the FDA approved beremagene geperpavec (B-VEC, Vyjuvek®), the first topical gene therapy for dystrophic epidermolysis bullosa (DEB). Before this milestone, only supportive care was available for patients living with DEB, focusing on wound care and symptom management rather than targeting the disease at its source. With B-VEC, clinicians gained a treatment that […]
